Q1 Earnings Estimate for AMLX Issued By Leerink Partnrs

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Amylyx Pharmaceuticals in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of ($0.52) for the quarter. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals' Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.49) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($1.70) EPS and FY2028 earnings at ($1.40) EPS.

Other analysts have also issued reports about the company. Mizuho upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $3.00 to $7.00 in a research report on Monday, April 7th. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $8.00.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock traded up $0.16 during trading hours on Wednesday, hitting $3.98. 724,313 shares of the company's stock were exchanged, compared to its average volume of 1,285,987. The stock has a market cap of $352.64 million, a price-to-earnings ratio of -1.04 and a beta of -0.53. Amylyx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $7.27. The stock's 50-day moving average is $3.56 and its 200-day moving average is $4.10.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter.

Insider Buying and Selling

In related news, Director Bernhardt G. Zeiher acquired 10,000 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were bought at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $37,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Joshua B. Cohen sold 21,490 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the sale, the chief executive officer now directly owns 3,355,280 shares of the company's stock, valued at $11,642,821.60. The trade was a 0.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,509 shares of company stock worth $222,586. Corporate insiders own 11.70% of the company's stock.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Boxer Capital Management LLC bought a new position in Amylyx Pharmaceuticals during the 4th quarter worth $6,615,000. Bank of America Corp DE raised its stake in Amylyx Pharmaceuticals by 165.9% in the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock worth $9,171,000 after purchasing an additional 1,513,748 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Amylyx Pharmaceuticals by 862.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company's stock valued at $1,786,000 after purchasing an additional 423,316 shares during the period. Jane Street Group LLC grew its position in shares of Amylyx Pharmaceuticals by 122.4% during the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company's stock worth $2,893,000 after purchasing an additional 421,302 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Amylyx Pharmaceuticals by 43.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company's stock worth $4,775,000 after purchasing an additional 382,608 shares during the period. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.